Just got my March 2024 AARP Bulletin magazine. Lo and behold, the front page special report, "The Future of Alzheimers - Why doctors have new hope about the disease and what that means for you" with subtitles of "Promising new research" and "The truth on dementia meds" POPS off the page.

The article mentions lecanemab (Leqembi), approved by the FDA, but states, "It doesn't stop, reverse or cure ... on average, it can slow mental decline by a mere 5 months over an 18 month treatment period.", then gives a list of dangers. Then, unbelievably, "... despite all these drawbacks, it represents a huge breakthrough..." It costs $6,636 annually even with Medicare. It also mentions Donanemab, expected to get approved this year, both of which clear amyloid plaque.

Then there's the NIH funded research section that talks about the stuff frequently mentioned on this board (targeting amyloid, BBB, blocking microglia, controlling neuroinflammation, etc.) and - wait for it - the importance of anti-inflammation research and drugs.

For those of you in the know, is Leronlimab even on the radar of all this research? Given everything I've learned from the collective expertise of this board, seems like Leronlimab would be the "miracle" that these other 2 drugs are not.